Holen Sie sich die Stockscreener-App
5.82
3.56%
0.20
Handel nachbörslich:
5.82
Schlusskurs vom Vortag:
$5.62
Offen:
$5.54
24-Stunden-Volumen:
333.47K
Relative Volume:
0.37
Marktkapitalisierung:
$580.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-299.80M
KGV:
-0.4801
EPS:
-12.1221
Netto-Cashflow:
$-217.49M
1W Leistung:
-7.32%
1M Leistung:
+16.87%
6M Leistung:
+33.79%
1J Leistung:
-36.25%
1-Tages-Spanne:
$5.43
$5.84
1-Wochen-Bereich:
$5.39
$6.47
52-Wochen-Spanne:
$3.36
$9.64
Acelyrin Inc Stock (SLRN) Company Profile
Firmenname
Acelyrin Inc
Sektor
Branche
Telefon
805-871-4300
Adresse
4149 LIBERTY CANYON RD., AGOURA HILLS
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-09-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-09-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-30 | Eingeleitet | Jefferies | Buy |
| 2023-05-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-05-30 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-30 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Acelyrin Inc Aktie (SLRN) Neueste Nachrichten
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(SLRN) Proactive Strategies - Stock Traders Daily
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.17 Consensus PT from Analysts - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Short Interest Update - MarketBeat
The Manufacturers Life Insurance Company Acquires 4,163 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (NASDAQ:SLRN) Trading Down 6.9%What's Next? - MarketBeat
(SLRN) Trading Advice - Stock Traders Daily
Acelyrin (NASDAQ:SLRN) Trading 4.8% Higher on Analyst Upgrade - MarketBeat
SLRNACELYRIN, INC. Latest Stock News & Market Updates - StockTitan
Wells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00 - MarketBeat
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease - The Manila Times
Did Acelyrin Inc (SLRN) perform well in the last session? - US Post News
Acelyrin (NASDAQ:SLRN) Stock Price Down 2.4%Should You Sell? - MarketBeat
Acelyrin Inc (SLRN) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Up 5.9%Still a Buy? - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Millennium Management LLC Has $20.47 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Renaissance Technologies LLC Has $1.75 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
160,167 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Bought by Susquehanna Fundamental Investments LLC - Defense World
Susquehanna Fundamental Investments LLC Takes Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Recent Insider Activity Suggests Potential Gains for Acelyrin Inc (SLRN) - Knox Daily
Almitas Capital LLC Buys New Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Piper Sandler maintains Overweight rating on Acelyrin shares - Investing.com
Piper Sandler maintains Overweight rating on Acelyrin shares By Investing.com - Investing.com Australia
Acelyrin Inc [SLRN] Director makes an insider sale of 1 shares worth $7.0. - Knox Daily
Top investors say Acelyrin Inc (SLRN) ticks everything they need - SETE News
Acelyrin Insider Sellers Miss The Bus As Stock Jumps 12% - Simply Wall St
Can Acelyrin Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Down 5.4% - MarketBeat
How did Acelyrin Inc (SLRN) fare last session? - US Post News
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch (NASDAQ:SLRN) - Seeking Alpha
Acelyrin (NASDAQ:SLRN) Shares Gap Up to $4.60 - MarketBeat
Acelyrin stock spikes on upcoming presentation (NASDAQ:SLRN) - Seeking Alpha
Acelyrin announces positive results from Phase 3 trial of izokibep - TipRanks
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 - StockTitan
Acelyrin Inc (SLRN) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Acadian Asset Management LLC Makes New $590,000 Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
In the Green: Acelyrin Inc (SLRN) Closes at 4.31, Up/Down -8.30 from Previous Day - The Dwinnex
Results from Acelyrin Inc (SLRN) show risk - US Post News
SLRN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Los Angeles Capital Management LLC Takes $693,000 Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc - Yahoo Finance
Significant Acquisition by T. Rowe Price Investment Management i - GuruFocus.com
Acelyrin announces PoC data from Phase 1/2 trial of lonigutamab - TipRanks
ACELYRIN reports positive Phase 1/2 trial data for TED therapy - Investing.com Australia
Acelyrin Inc (SLRN) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of - The Bakersfield Californian
Acelyrin, Inc. (NASDAQ:SLRN) Receives $10.83 Average Target Price from Analysts - MarketBeat
How does Acelyrin Inc (SLRN) change from a tortoise to a hare? - SETE News
Is it possible to buy Acelyrin Inc(SLRN) shares at a good price now? - US Post News
Finanzdaten der Acelyrin Inc-Aktie (SLRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.11%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):